HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

Eli Lilly's (LLY) cease-and-desist letter is dismissed by weight loss drug compounder, OrderlyMeds. Read more here.

GLP-1 drugs are blockbuster medications for weight loss and Type 2 diabetes. Now doctors are trying them for lymphedema, ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

New research to be presented at this year's European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

While most guidelines require 6 months of behavioral interventions before prescribing weight-loss drugs, new research shows ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established atherosclerotic disease, CKD, or both.

This might mean decreasing the risk for diabetes or high cholesterol, two conditions that are common in people with PCOS. Research backs this up: when using GLP-1s to aid in weight loss ...

and included over 162,000 patients split into matched pairs (meaning: one control subject, one experimental subject). Not all GLP-1 drugs had the same psychiatric effects: Ozempic was associated ...